|Mr. Peter K. Miller||CEO & Director||999.81k||N/A||1961|
|Dr. Ramy A. Mahmoud M.D., M.P.H.||Pres & COO||737.55k||N/A||1965|
|Mr. Keith Alan Goldan||Chief Financial Officer||600.21k||N/A||1971|
|Mr. Michael F. Marino||Chief Legal Officer & Corp. Sec.||604.71k||N/A||1976|
|Mr. Victor M. Clavelli||Chief Commercial Officer||584.2k||N/A||1973|
|Mr. Jonathan Neely||VP of Investor Relations & Bus. Operations||N/A||N/A||N/A|
|Ms. Karen E. Brophy||VP of HR||N/A||N/A||1963|
|Mr. John Messina||Sr. VP of Clinical Devel. & Medical Affairs||N/A||N/A||N/A|
|Ms. Helena Kyttari Djupesland||Co-Founder of Optinose AS (Norway) & Co-CEO of Optinose AS (Norway)||N/A||N/A||N/A|
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase 3b clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.
OptiNose, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 7. The pillar scores are Audit: 7; Board: 6; Shareholder Rights: 8; Compensation: 8.